CTSO vs. LNSR, DXR, LUCD, CTCX, APYX, XAIR, AMIX, ICCM, DRIO, and MODD
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include LENSAR (LNSR), Daxor (DXR), Lucid Diagnostics (LUCD), Carmell (CTCX), Apyx Medical (APYX), Beyond Air (XAIR), Autonomix Medical (AMIX), IceCure Medical (ICCM), DarioHealth (DRIO), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
Cytosorbents (NASDAQ:CTSO) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Cytosorbents has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
In the previous week, Cytosorbents had 3 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Cytosorbents and 2 mentions for LENSAR. LENSAR's average media sentiment score of 1.13 beat Cytosorbents' score of 0.37 indicating that LENSAR is being referred to more favorably in the news media.
Cytosorbents received 431 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 79.27% of users gave Cytosorbents an outperform vote while only 38.46% of users gave LENSAR an outperform vote.
32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Comparatively, 38.5% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cytosorbents currently has a consensus target price of $2.00, suggesting a potential upside of 106.70%. LENSAR has a consensus target price of $8.00, suggesting a potential upside of 94.17%. Given Cytosorbents' higher probable upside, research analysts plainly believe Cytosorbents is more favorable than LENSAR.
LENSAR has a net margin of -27.57% compared to Cytosorbents' net margin of -75.07%. LENSAR's return on equity of -36.53% beat Cytosorbents' return on equity.
LENSAR has higher revenue and earnings than Cytosorbents. LENSAR is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Summary
LENSAR beats Cytosorbents on 9 of the 17 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
